A detailed history of Cooper Financial Group transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Cooper Financial Group holds 533 shares of REGN stock, worth $366,597. This represents 0.05% of its overall portfolio holdings.

Number of Shares
533
Previous 599 11.02%
Holding current value
$366,597
Previous $629,000 39.75%
% of portfolio
0.05%
Previous 0.08%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 13, 2025

SELL
$701.85 - $1046.91 $46,322 - $69,096
-66 Reduced 11.02%
533 $379,000
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $327,708 - $384,563
320 Added 114.7%
599 $629,000
Q2 2024

Jul 15, 2024

BUY
$883.2 - $1071.19 $246,412 - $298,862
279 New
279 $293,000
Q2 2022

Jul 11, 2022

SELL
$548.35 - $738.84 $303,237 - $408,578
-553 Closed
0 $0
Q1 2022

Apr 12, 2022

BUY
$595.12 - $698.43 $329,101 - $386,231
553 New
553 $386,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $73.7B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Cooper Financial Group Portfolio

Follow Cooper Financial Group and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cooper Financial Group, based on Form 13F filings with the SEC.

News

Stay updated on Cooper Financial Group with notifications on news.